Results 21 to 30 of about 5,633 (170)

Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice

Revista da Sociedade Brasileira de Medicina Tropical, 2014
Introduction The treatment of leishmaniasis ischallenging, given the difficulties in drug administration and resistance. Therefore, we chose to test the efficacy of miltefosine combined with pentoxifylline.
Ana Angélica Amorim Santarem, Gabriel Frizon Greggianin, Rafaela Garcia Debastiani, Jefferson Bruno Pereira Ribeiro, Demerson Andre Polli, Raimunda Nonata Ribeiro Sampaio   +5 more
doaj   +1 more source

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.

PLoS Neglected Tropical Diseases, 2016
BackgroundSSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization.
Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P C Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E Kip, Gerard J Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa   +22 more
doaj   +1 more source

Miltefosine [PDF]

Reactions Weekly, 2020
Ramy H. Elshaboury, Ronak G. Gandhi
  +5 more sources

Lipid raft‐disrupting miltefosine preferentially induces the death of colorectal cancer stem‐like cells

Clinical and Translational Medicine, 2021
Background Lipid rafts (LRs), cholesterol‐enriched microdomains on cell membranes, are increasingly viewed as signalling platforms governing critical facets of cancer progression.
So‐Yeon Park, Jee‐Heun Kim, Jang‐Hyun Choi, Choong‐Jae Lee, Won‐Jae Lee, Sehoon Park, Zee‐Yong Park, Jeong‐Heum Baek, Jeong‐Seok Nam   +8 more
doaj   +1 more source

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.

PLoS Neglected Tropical Diseases, 2017
BackgroundOral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children.
Brandon A Berger, Alexandra Cossio, Nancy Gore Saravia, Maria Del Mar Castro, Sergio Prada, Allison H Bartlett, Mai T Pho   +6 more
doaj   +1 more source

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.

PLoS Neglected Tropical Diseases, 2010
BackgroundCutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance.Methodology/principal ...
Paulo R Machado, Julia Ampuero, Luiz H Guimarães, Leonardo Villasboas, Ana T Rocha, Albert Schriefer, Rosana S Sousa, Anette Talhari, Gerson Penna, Edgar M Carvalho   +9 more
doaj   +1 more source

Vectors and Vector‐Borne Diseases: Biology, Epidemiology and Integrated Control Strategies

Journal of Applied Entomology, EarlyView.
ABSTRACT Vector‐Borne Diseases (VBDs), transmitted by arthropods such as mosquitoes, ticks, fleas and sandflies, represent a significant threat to global health. These diseases can be caused by a variety of pathogens, including bacteria, viruses, protozoa, and helminths.
Roberta Rinaldi, Carmen Scieuzo, Federica De Stefano, Luca Masucci, Patrizia Falabella   +4 more
wiley   +1 more source

The zinc cluster transcription factor Znc1 regulates Rta3-dependent miltefosine resistance in Candida albicans

mSphere
Zinc cluster transcription factors (ZCFs) are a family of transcription regulators that are almost exclusively found in the fungal kingdom. Activating mutations in the ZCFs Mrr1, Tac1, and Upc2 frequently cause acquired resistance to the widely used ...
Bernardo Ramírez-Zavala, Ines Krüger, Sonja Schwanfelder, Katherine S. Barker, P. David Rogers, Joachim Morschhäuser   +5 more
doaj   +1 more source

Structural basis of ligand selectivity in FAD/NAD(P)H‐dependent dehydrogenases: insights from trypanothione reductase and type II NADH dehydrogenase

Protein Science, Volume 35, Issue 7, July 2026.
Abstract FAD/NAD(P)H‐dependent dehydrogenases form a structurally conserved family of redox enzymes that participate in essential metabolic processes across parasites and higher organisms. Among them, trypanothione reductase (TR) is a key component of the redox metabolism of Leishmania species and represents an attractive target for antileishmanial ...
Giulia Chiara Maria Perrone, Serena Spadone, Anna Lucia Francavilla, Sara Morselli, Sabino Todisco, Margherita Ortalli, Jairo Alfonso Mendoza‐Roldan, Valeria Scaglione, Maria Noemi Sgobba, Lorenzo Guerra, Federica Belluti, Stefania Varani, Domenico Otranto, Anna De Grassi, Mariateresa Volpicella, Ciro Leonardo Pierri   +15 more
wiley   +1 more source

Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer

Immunology, Volume 178, Issue 3, Page 377-386, July 2026.
Conceptual ‘Crossroads Model’ linking Leishmania, thymic infection and immune dysregulation: an integrative model is proposed in which Leishmania infection disrupts thymic architecture and stromal–thymocyte interactions. These alterations converge to promote defective tolerance, increased autoimmune risk and a microenvironment permissive to malignant ...
Alef Batista Bezerra Barros, Gabriel Augusto Leite, Arthur Gomes de Andrade, Maria Danielma dos Santos Reis, Luiz Henrique Agra Cavalcante‐Silva, Marvin Paulo Lins   +5 more
wiley   +1 more source